Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study

被引:0
作者
Ogar, Comfort K. [1 ]
Gilbert, Hannah N. [2 ]
Bloem, Lourens T. [1 ]
Leopold, Christine [1 ]
Bassi, Peter U. [3 ]
Katagum, Yahaya M. [4 ]
Osakwe, Adeline I. [5 ]
Opadeyi, Abimbola O. [6 ]
Oreagba, Ibrahim [7 ]
Mbo, Danjuma N. D. [8 ]
Mantel-Teeuwisse, Aukje K. [1 ]
De Bruin, Marie L. [1 ]
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[2] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA
[3] Univ Abuja, Coll Hlth Sci, Dept Internal Med, Abuja, Nigeria
[4] Bauchi State Univ, Dept Clin Pharm & Pharm Adm, Gadau, Nigeria
[5] A Line Pharmaceut, Nsukka, Enugu, Nigeria
[6] Univ Benin, Teaching Hosp, Coll Med Sci, Dept Clin Pharmacol & Therapeut, Benin, Nigeria
[7] Univ Lagos, Coll Med, Dept Pharmacol Therapeut & Toxicol, Lagos, Nigeria
[8] Maitama Dist Hosp, Dept Internal Med, Abuja, Nigeria
关键词
Patient reported outcomes; Adverse events following immunization (AEFI); COVID-19; vaccines; Vaccination; Health-related quality of life; Nigeria; QUALITY-OF-LIFE; DRUG-REACTIONS; HEALTH-CARE; SF-36; PRO;
D O I
10.1016/j.vaccine.2024.126196
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Adverse events following immunization (AEFIs), especially if serious, may impact vaccine recipients' quality of life and financial well-being and fuel vaccine hesitancy. Nigeria rolled out COVID-19 vaccination in 2021 with little known about the impact of AEFIs on an individual's quality of life. No study in Africa has explored the health and financial impact of AEFIs. We explored patient-reported outcomes (PROs) of adverse events after COVID-19 vaccination and documented the lived experiences of those with serious AEFIs to understand the effect on their health, financial well-being, and attitude to future vaccinations.<br /> Methods: We conducted a convergent mixed-methods study using the RAND 36-item health survey and in-depth interviews to collect PROs on vaccine recipients in Nigeria. Eight health scale scores and two summary composite scores were used to measure the health-related quality of life outcomes from the survey and inductive analysis was used to identify themes from the interview scripts. The results of both studies were integrated in a joint display to highlight areas of concordance.<br /> Results: In total, 785 survey responses were analyzed (53% females, 68% aged 18-30 years). Responders reporting an AEFI were 58%, of whom 62% received the first dose only. Younger age and first vaccine dose (p < .001 respectively) were associated with experiencing an AEFI. Not reporting an AEFI was associated with better quality of life, measured as higher scores on all eight SF-36 Health scales and the physical and mental component summary scores. All six interviewees with serious AEFIs experienced physical, mental, and financial distress. Some expressed a strong negative attitude toward future COVID-19 vaccinations but not toward vaccines for routine immunization. Conclusion: AEFIs negatively impact the health and financial well-being of affected individuals and their attitude to future vaccinations, especially if serious. Understanding the impact of AEFIs on people is important and should inform future policies and interventions. The results of our study can inform policy and planning for future mass vaccination campaigns in LMICs.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The Use of Patient-reported Outcomes (PRO) Within Comparative Effectiveness Research Implications for Clinical Practice and Health Care Policy
    Ahmed, Sara
    Berzon, Richard A.
    Revicki, Dennis A.
    Lenderking, William R.
    Moinpour, Carol M.
    Basch, Ethan
    Reeve, Bryce B.
    Wu, Albert W.
    [J]. MEDICAL CARE, 2012, 50 (12) : 1060 - 1070
  • [2] [Anonymous], 2017, Guideline on good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies (Rev 3)
  • [3] [Anonymous], 2011, Designing and conducting mixed method research
  • [4] Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries
    Bots, Sophie H. H.
    Riera-Arnau, Judit
    Belitser, Svetlana V. V.
    Messina, Davide
    Aragon, Maria
    Alsina, Ema
    Douglas, Ian J. J.
    Duran, Carlos E. E.
    Garcia-Poza, Patricia
    Gini, Rosa
    Herings, Ron M. C.
    Huerta, Consuelo
    Sisay, Malede Mequanent
    Martin-Perez, Mar
    Martin, Ivonne
    Overbeek, Jetty A. A.
    Paoletti, Olga
    Palleja-Millan, Meritxell
    Schultze, Anna
    Souverein, Patrick
    Swart, Karin M. A.
    Villalobos, Felipe
    Klungel, Olaf H. H.
    Sturkenboom, Miriam C. J. M.
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Myocarditis With COVID-19 mRNA Vaccines
    Bozkurt, Biykem
    Kamat, Ishan
    Hotez, Peter J.
    [J]. CIRCULATION, 2021, 144 (06) : 471 - 484
  • [6] Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states
    Buhl, Caroline
    Jacobsen, Ramune
    Almarsdottir, Anna Birna
    Abtahi, Shahab
    Andersen, Armin
    Deligianni, Elena
    Dermiki-Gkana, Foteini
    Kontogiorgis, Christos
    Oikonomou, Chara
    Kursite, Mirdza
    Poplavska, Elita
    Hegger, Ingrid
    Goot, Marloes van der
    Ferreira, Paula Barao Sousa
    Ribeiro-Vaz, Ines
    Silva, Ana Marta
    Kos, Mitja
    Lipovec, Nanca Cebron
    van Vliet, Ella
    Alves, Teresa Leonardo
    [J]. VACCINE, 2024, 42 (03) : 556 - 563
  • [7] Maximising the impact of patient reported outcome assessment for patients and society
    Calvert, Melanie
    Kyte, Derek
    Price, Gary
    Valderas, Jose M.
    Hjollund, Niels Henrik
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 364
  • [8] Committee for Medicinal Products for Human Use, 2005, REFL PAP REG GUID US
  • [9] Patient-reported outcomes in vaccines research: relevance for decision-making
    Curran, Desmond
    Cabrera, Eliazar Sabater
    Nelsen, Linda
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01) : 1 - 8
  • [10] Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
    Davies, Emma C.
    Green, Christopher F.
    Taylor, Stephen
    Williamson, Paula R.
    Mottram, David R.
    Pirmohamed, Munir
    [J]. PLOS ONE, 2009, 4 (02):